Days alive and out of hospital after treatment for oropharyngeal squamous cell carcinoma with primary transoral robotic surgery or radiotherapy – a prospective cohort study
Susanne Irene Scott, Anne Kathrine Østergaard Madsen, Niclas Rubek, Henrik Kehlet, Christian von Buchwald
Abstract
Background With the rising incidence of oropharyngeal squamous cell cancer, there is a need to assess the burden of treatment.Aims/objectives This study assessed ‘days alive and out of hospital’ (DAOH) in a cohort of patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with either transoral robotic surgery (TORS) or radiotherapy (RT).Material and methods A prospective cohort study conducted between May 2017–June 2019. Primary outcome was DAOH in the first 30 days after treatment (DAOH30). The secondary outcome was DAOH180.Results Forty-four patients were included, 31 treated with TORS and 13 with RT. Patients treated with TORS had a median DAOH30 of 25 (IQR 22.8–26) including a required four-day postoperative stay- and a median DAOH180 of 168 (IQR 163–171.3). In contrast, patients treated with RT had a median DAOH30 of 30 (IQR 26–30) and a DAOH180 of 143 days (IQR 135.5–149).Conclusions and Significance DAOH has not been examined in oropharyngeal cancer before. We found, patients overall spent 92.5% of the first 180 days alive and out of hospital. Patients treated with TORS had high DAOH30, which remained high in DAOH180, while patients treated with RT with reduced DAOH30, had reduced DAOH180 calling for further large-scale studies.